niftify.in

The Economic Times

Highway Infrastructure, Jaro Education file DRHPs with Sebi to raise funds through IPO

Highway Infrastructure Ltd (HIL) filed for an IPO, including a fresh issue of Rs 105 crore and an OFS of Rs 310 crore. HIL is engaged in tollway collection, infrastructure development, and real estate. Jaro Institute of Technology Management and Research also filed for an IPO, with a fresh issue of Rs 170 crore and an OFS of Rs 400 crore by promoter Sanjay Namdeo Salunkhe. Jaro Education plans to use proceeds for marketing, debt repayment, and general corporate purposes.

The Economic Times

Are digital tools a way for companies to retain hourly workers?

WorkJam, an online platform that was founded in 2014, provides clients such as Target, Ulta Beauty and Hilton with digital tools their non-salaried employees can use to swap shifts, complete trainings and get early access to wages.

Business Standard

Blackstone real estate's Bill Stein retiring after almost 30 years

Stein, a senior managing director, was involved in signature Blackstone holdings including Hilton Worldwide, casino resort Cosmopolitan of Las Vegas and single-family home landlord Invitation Homes

The Economic Times

Ventive Hospitality files draft prospectus with Sebi for Rs 2,000 crore IPO

Ventive Hospitality has filed its draft red herring prospectus with Sebi for a Rs 2,000 crore IPO. The company, owning luxury assets operated by global brands like Marriott and Hilton, features 11 assets across India and Maldives.

CNBC TV18

Shilpa Medicare submits new drug application to USFDA for kidney disease treatment, stock hits all-time high

Shilpa Medicare Share Price | Shilpa Medicare submitted the NDA to the USFDA by Unicycive Therapeutics, its first regulatory submission from CDMO partnered projects.

Business Standard

Hilton to tap luxury travel trend in Asia Pacific, eyes 150 properties

Global hospitality major Hilton on Wednesday said it plans to cross 150 luxury hotels in the Asia Pacific region in the coming years, driven by new openings including India. The company, which plans to quadruple its luxury portfolio across the region compared with the end of 2023, is seeking to tap the rising luxury travel trend and a desire among customers to better understand their heritage through travel. "From Tokyo to Maldives, Shanghai to Jaipur '? the luxury segment is growing exponentially and Hilton's luxury brands are poised to capture the significant opportunity across the region," Hilton Asia Pacific President Alan Watts said in a statement. The company said the addition of properties, such as Lanson Place Causeway Bay Hong Kong and Gangtey Lodge, Bhutan from Small Luxury Hotels of the World, Hilton's luxury pipeline in Asia Pacific continues to gain momentum. Recent signings, including Waldorf Astoria Jaipur and Conrad Jaipur in India, and Conrad Yokohama in Japan, ...

The Economic Times

Rocket Returns: This Madhusudhan Kela and Sunil Singhania-owned smallcap stock has rallied 45% since April QIP

Shilpa Medicare, held by Madhusudhan Kela and Sunil Singhania, has returned 45% since its QIP allotment four months ago. Singhania's Abakkus Diversified Alpha Fund-2 received 6 lakh shares, while Kela’s Cohesion MK Best Ideas Sub-Trust was allotted 8.79 lakh shares.

The Economic Times

Shilpa Medicare completes phase-3 trial of novel therapy against nonalcoholic fatty liver disease, shares gain

Shilpa Medicare's shares surged 6.40% on BSE following the successful phase-3 clinical trials of Nor Ursodeoxycholic Acid tablets for Nonalcoholic Fatty Liver Disease. Conducted on 165 patients across India, the trial revealed significant improvements in liver health and reduced fat accumulation with no serious adverse events.

Business Standard

Shilpa Medicare hits fresh high on successful trial of liver fibrosis drug

Shares of Shilpa Medicare were trading at Rs 733.15, up by nearly Rs 36, or 5.15 per cent on the BSE. In contrast, the 30-stock BSE Sensex was trading at 81,714 levels, up 0.77 per cent.

CNBC TV18

Shilpa Medicare shares near record high after 12% surge on this positive development

A total of 165 Nonalcoholic fatty liver disease (NAFLD) patients across the country participated in the study of this new drug, making the trial a multicentric, placebo-controlled double-blinded study.

Mint

Shilpa Medicare soars over 11% to record high on positive phase 3 trial results for fatty liver drug NorUDCA

Shilpa Medicare shares surged over 11% after announcing successful Phase 3 trials for NorUDCA, a drug for Nonalcoholic Fatty Liver Disease (NAFLD).